Below are key performance indicators (KPIs) for each of our four focus areas (Access to Health, Employees, Environmental Sustainability, and Ethics & Values), as well as links to the performance data tables found throughout this site.
These KPIs serve as baseline measurements for our corporate responsibility activities, are measured globally unless otherwise noted, and cover all of our business units with the exception of joint ventures.
Access to Health
Key Performance Indicators (KPIs)
|Research & Development||2014||2015||2016||2017||2018|
|Top 20 global burdens of disease addressed by our products and pipeline1||88%||88%||88%||88%||88%|
|GCP/PV inspections by regulatory agencies of the company or clinical trial investigators that led to significant fines, penalties, warning letters or product seizures2||0||0||–||0||0|
|Established significant external licenses and collaborations3||35||64||57||55||64|
|Narrative of compounds provided to product-development partnerships4||Online|
|Manufacturing & Supply||2014||2015||2016||2017||2018|
|Annual percentage of units manufactured/sold and recalled during a given year (recall rate globally)5, 6||0.22%||0.07%||0.01%||0.01%||0.14%|
|Number of local and regional manufacturing partnerships to enable access||104||179||179||153||144|
|Number of products available through local and regional partnerships7||499||1,157||941||765||700|
|New product and device registrations (annual) 8, 9, 10||176||156||143||143||124|
|Products submitted that have achieved WHO prequalification||11||11||11||13||13|
|Number of products that are supported with differential pricing11, 12||35||35||40||42||42|
|Number of countries where inter- and/or intra-country pricing has been implemented13||114||121||123||125||128|
|Investment in patient- and provider-education programs (in millions)||$52||$80||$80||$90||$115|
|NOTE: Year-over-year differential pricing performance metrics can be impacted based on the timing of local-market or third-party contract renewals and/or product life-cycle introductions or deletions. Therefore, increases or decreases in these pricing metrics should not be interpreted as anticipating the level of trend growth in future years.|
|Health care workers trained through major programs and partnerships (estimate)14||137,000||19,000||32,000||74,000||67,000|
|Investment in partnerships for activities to address underlying barriers to health, such as health-system strengthening and capacity building (in millions)14||$32||$21||$28||$40||$37|
|People reached through major programs & partnerships (in millions)15||267||188||293||311||357|
|Note: Unless otherwise stated, data for Access to Health are reflective of our Human Health business only; information on our company's Animal Health is reported separately.|
1 As defined by the Institute for Health Metrics and Evaluation (IHME), which replaces the previously used WHO chart of leading causes of disease, condition or injury.
2 Complete response letter received for Sugammadex (MK-8616) in 2013, and the complete response letter received for Januvia (sitagliptin; MK-0431) in 2016.
3 Starting in 2014, this metric no longer includes select early licenses and research collaborations that were included in the metric for previous years.
4 For information on product-development partnerships, visit https://www.msdresponsibility.com/access-to-health/research-development/.
5 Definition of Recall Classifications: http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm049070.htm#RecallClassifications
6 Starting in 2014, product recalls include data from our Animal Health business.
7 Increase represented in 2015 is due in part by better visibility to global partner information.
8Data includes new products and new indications.
9For information on new registrations by region, visit our Clinical Research section.
10Data for all years have been updated based on a tracking system upgrade that corrected miscounts in prior years.
11Differential pricing intended to facilitate access for the at-need population.
12Products include HIV treatments, vaccines and other patented products.
13Countries as defined by the World Bank 2017 GNI Classification, including UN-defined Least Developed Countries.
14Represents investments by our Office of Social Business Innovation, including our Office of Corporate Responsibility, MSD for Mothers and our company’s Foundation.
- Animal Health
- Clinical Research
- Manufacturing & Supply
- MECTIZAN® (ivermectin) Donation Program
- MSD Medical Outreach Program (MMOP)
- MSD for Mothers
- Patient Assistance Programs
- Product Pricing
- Product Registration
- Quality & Product Safety
- Research & Development
- Social Investments
- Women’s Health
Key Performance Indicators (KPIs)
|Diversity & Inclusion||2014||2015||2016||2017||2018|
|Women in executive roles1||31%||34%||31%||32%||32%|
|Women on the Board||17%||21%||23%||23%||23%|
|Members of underrepresented ethnic groups on the Board||25%||21%||23%||23%||23%|
|Members of underrepresented ethnic groups in executive roles (U.S.)||20%||20%||23%||23%||21%|
|Members of underrepresented ethnic groups in the workforce (U.S.)||24%||26%||26%||26%||27%|
|Response rate to the Voice Survey||78%||NA||85%||NA||86%|
|Employees who completed a health assessment (U.S.)2||57%||58%||57%||70%||NA|
|Lost-time incident rate (LTIR)||0.20||0.22||0.13||0.13||0.1|
|Recordable injury rate (RIR)||0.58||0.48||0.35||0.33||0.3|
|Employees who took release time according to the global policy on employee volunteerism3||NA||9.0%||21.0%||7.0%||7.0%|
|Total recorded volunteer hours4||109,932||80,585||214,862||114,903||114,393|
|NA: Not Available.|
1 “Executive” is defined as the chief executive officer and two structural levels below.
2 Did not capture health assessment data in 2018 due to change in vendor.
3 Company population figures are based on an estimated workforce of approximately 66,000 in 2018.
4 2018 figures are based on employee self-recorded volunteer hours and volunteer hours communicated directly to the Office of Corporate Responsibility for certain countries. 2015 marked the first year in which volunteer hour reporting was based solely on employee self-reporting. Prior years included estimates for unrecorded volunteer hours.
Key Performance Indicators (KPIs)1
|Greenhouse gas emissions (Scope 1 & 2) (MT CO2e)2||1,532,400||1,416,400||1,363,300||1,254,700||1,208,100|
|Water usage (m3)||26.9||24.0||20.7||19.6||20.5|
|Operational waste generated (MT)||83,732||69,856||72,599||72,426||73,930|
|1 Includes facilities worldwide.|
2 In accordance with the Greenhouse Gas Protocol, prior-year data have been adjusted to add or remove facilities that have been acquired or sold. Adjustments also reflect changes in methodology to ensure consistency from year to year.
Ethics & Values
Key Performance Indicators (KPIs)
|Employees trained on our Code of Conduct training series||99%||99%||100%||100%||99%|
|Ratio of substantiated allegations to concerns/issues raised||60%||58%||55%||60%||52%|
|Reported concerns regarding privacy practices, breaches of privacy and losses of personal data and devices that were substantiated1, 2||18%||96%||98%||98%||97%|
|1 Privacy concerns include all concerns escalated to our Privacy Office about the company’s privacy practices. Substantiated concerns are those that are determined to be inconsistent with our privacy standards or that involve the loss of, theft of or unauthorized access to personal data.|
2 In 2015, because of the scope of lost or stolen devices known to be encrypted, we ceased inclusion of lost or stolen MSD devices in our incident metrics.